BLT2, a leukotriene B4 receptor 2, as a novel prognostic biomarker of triple-negative breast cancer

Triple-negative breast cancer (TNBC) is considered to be a notorious type of cancer due to its aggressive metastatic potential and poor prognosis. Recent evidence suggests that BLT2, a low-affinity LTB 4 receptor is critically associated with the phenotypes of TNBC cells, including invasion, metasta...

Full description

Saved in:
Bibliographic Details
Published in:BMB reports 2018-08, Vol.51 (8), p.373
Main Authors: Jaein Park, Jae-hyun Jang, Geun-soo Park, Yunro Chung, Hye Jin You, Jae-hong Kim
Format: Article
Language:Korean
Subjects:
BLT2
Leukotriene B4 receptor-2
TNBC
Triple-negative breast cancer
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Triple-negative breast cancer (TNBC) is considered to be a notorious type of cancer due to its aggressive metastatic potential and poor prognosis. Recent evidence suggests that BLT2, a low-affinity LTB 4 receptor is critically associated with the phenotypes of TNBC cells, including invasion, metastasis, and survival. Furthermore, in a group of 545 breast cancer patients with metastasis, we observed that the high-BLT2 subgroup had a lower disease-free-survival rate than the low-BLT2 subgroup. Thus, we theorized that anti-BLT2 strategies could facilitate the development of new therapies used for TNBC. This review focuses on recent discoveries regarding BLT2 and its roles in as a novel prognostic biomarker in TNBC. [BMB Reports 2018; 51(8): 373-377]
ISSN:1976-6696